StockGuru Profile MZEI – Started June 2 at 4.1 cents – Today closed at $0.275 – A gain of 570% – Millions in Volume This Week and Today
STOCKGURU PROFILE FOR MEDIZONE - CORPORATE WEB SITE
Hi Everyone,
Our remarkable day closed up 30.95% at $0.275. That is terrific and well justified in my opinion. We started this one at the beginning of Summer. The more I learned about the stock, the more I liked it.
The close the day prior to our start was just $0.041 – That is FOUR POINT ONE CENTS.
The potential for members is a 570% increase if you bought at that low and held it through today’s high.
There were many, many single digit opportunities for MZEI. I doubt we’ll see any of those opportunities return.
Some ask: “John, have you ever SOLD as share?” The answer is NO. I have restricted, and my restricted was given to me when the stock was in the $0.041 range. I proudly hold it today.
To be up front – I think AsepticSure (TM) is going to be huge. A SIX LOG REDUCTION in MRSA is incredible. That is 99.9999 less of the virus. This works on many other pathogens. The company is nearing sell and deployment. It will save lives and huge sums of money. (Could it pay for Obamacare? – Okay – we need some humor!)
Seriously – please do your due diligence and learn about MZEI. Even if you are already holding shares, learn about this company some more. Know the potential of the shares you now have.
Good luck to all. I think even better days are ahead.
John Pentony
Publisher, StockGuru.com
Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
